Kyntra Bio Inc.
KYNB | NASDAQ
$4.57
-$0.08 (-1.72%)
At close: Oct 30, 2026, 4:00 PM ET
$4.51
-$0.06 (-1.31%)
Pre-market:
Nov 2, 2026, 7:36 AM ET
Company Profile
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Thane Wettig | Chief Executive Officer & Director |
| David DeLucia | Senior Vice President & Chief Financial Officer |
| Carol Gaddum | Vice President of Product Development |
| Carrie Brownstein | Chief Medical Officer |
| Gaia Vasiliver-Shamis | Director of IR & Communications - LifeSci Advisors |
| John Alden | Corporate Secretary & General Counsel |
| Michelle Simonetti | Head of People and Culture & Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 01, 2026 | 8-K | Current Report |
| Sep 09, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Aug 31, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K | Current Report |
| Jun 17, 2026 | 4 | Filing |
| Jun 17, 2026 | 4 | Filing |
| Jun 17, 2026 | 4 | Filing |
Kyntra Bio Inc.
| Country | United States |
| IPO Date | Nov 14, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Thane Wettig |
Contact Details
350 Bay Street San Francisco,
California 94133 United States
Stock Details
| Ticker Symbol | KYNB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000921299 |
| CUSIP Number | 31572Q881 |
| ISIN Number | US31572Q8814 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove KYNB